Esperion Therapeutics (ESPR) Stock Analysis & Winston Score

Esperion Therapeutics is a pharmaceutical company focused on lowering bad cholesterol (LDL-C) in patients who can't get their levels under control with standard treatments like statins. Its main products are Nexletol and Nexlizid, two oral pills that work through a different mechanism than statins, targeting patients with high cardiovascular risk. The company sells primarily to cardiologists and primary care doctors in the United States and has a commercial partnership with Daiichi Sankyo for sales in Europe. Esperion makes money by selling these prescription drugs directly to pharmacies and through specialty distributors, earning revenue each time a prescription is filled. The company operates mainly in the US, with European royalties adding a secondary income stream, and its competitive edge comes from being one of the few non-statin oral options approved for LDL reduction. The key growth driver is expanding the prescriber base and gaining broader insurance coverage, while the main risk is competition from injectable PCSK9 inhibitors, which are highly effective alternatives in the same patient population.